tHEORetically Speaking
Insights, observations, and executive interviews that discuss data and evidence to guide value-based decisions in health care. For more, visit our blog: https://healtheconomics.com/theoretically-speaking/
tHEORetically Speaking
Weekly News Roundup – Pharma Acquisitions, Trial Triumphs, and Coding Controversies
•
HealthEconomics.com
•
Season 4
•
Episode 13
This week’s tHEORetically Speaking News Roundup covers new research on social-genetic influences in adolescent depression, Novartis’s $1.4B acquisition of Tourmaline Bio for a promising heart drug, and encouraging Phase 2 results for rezatapopt in solid tumors. We also explore the FDA’s draft guidance on non-opioid pain treatments and the AMA’s release of 2026 CPT codes amid growing scrutiny.
Tune in for this concise recap of these pivotal industry updates!